Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.
Histologically confirmed first diagnosis of cHL
Advanced-stage disease: stage IIB with large mediastinal mass and/or extranodal lesions or stage III or IV
No previous treatment for HL with the exception of steroid prephase
Confirmed HIV infection with CD4 counts ≥ 150/μL at registration or > 250/μL at any time within 8 months prior to HL diagnosis
Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment
Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Multi-drug resistant HIV infection or concurrent AIDS-defining conditions
Pregnancy or breastfeeding
Single group
BrECADD
DrugBrentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone
Progression Free Survival
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
